-
Je něco špatně v tomto záznamu ?
Silybin is metabolized by cytochrome P450 2C8 in vitro
P Jancova, E Anzenbacherova, B Papouskova, K Lemr, P Luzna, A Veinlichova, P Anzenbacher, V Simanek
Jazyk angličtina Země Spojené státy americké
- MeSH
- antioxidancia farmakologie metabolismus MeSH
- aromatické hydroxylasy antagonisté a inhibitory genetika metabolismus MeSH
- cytochrom P-450 CYP1A2 genetika metabolismus MeSH
- cytochrom P-450 CYP3A MeSH
- Escherichia coli genetika metabolismus MeSH
- financování organizované MeSH
- inhibitory cytochromu P450 CYP1A2 MeSH
- inhibitory cytochromu P450 MeSH
- inhibitory enzymů farmakologie metabolismus MeSH
- jaterní mikrozomy enzymologie metabolismus účinky léků MeSH
- katalýza účinky léků MeSH
- lidé MeSH
- molekulární struktura MeSH
- oxid uhelnatý farmakologie MeSH
- quercetin farmakologie MeSH
- rekombinantní proteiny metabolismus MeSH
- silymarin farmakologie chemie metabolismus MeSH
- systém (enzymů) cytochromů P-450 genetika metabolismus MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- Check Tag
- lidé MeSH
Silybin (a flavonolignan, the main component of silymarin, an extract from the seeds of Silybum marianum) has been used to date mostly as a hepatoprotectant. However, it also has other interesting activities, e.g., anticancer and hypocholesterolemic effects. It is also known that silybin can inhibit the activities of the cytochrome P450 (P450) enzymes. In this study, a weak interaction of silybin with human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC(50) > or = 250 microM) was found; a moderate inhibition was observed for CYP1A2 and 2C8. The most prominent inhibition effect was found with CYP3A4 and CYP2C9 (IC(50) < or = 50 microM). Using mass spectometry detection, production of O-demethylated (the main metabolite) as well as hydroxylated derivatives of silybin formed by P450 enzymes was detected. The effect of different P450 inhibitors on the formation of O-demethylated product was also studied. In particular, a relatively specific inhibitor of CYP2C8 (quercetin) markedly inhibited the formation of this metabolite. With the help of recombinant enzymes (bactosomes), it was confirmed that the CYP2C8 enzyme is responsible for the reaction leading to O-demethylated silybin.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10026807
- 003
- CZ-PrNML
- 005
- 20111210192459.0
- 008
- 101019s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jančová, Petra $7 xx0114108
- 245 10
- $a Silybin is metabolized by cytochrome P450 2C8 in vitro / $c P Jancova, E Anzenbacherova, B Papouskova, K Lemr, P Luzna, A Veinlichova, P Anzenbacher, V Simanek
- 314 __
- $a Faculty of Medicine, Department of Medical Chemistry and Biochemistry, Faculty of Sciences, Palacky University at Olomouc, Olomouc, Czech Republic.
- 520 9_
- $a Silybin (a flavonolignan, the main component of silymarin, an extract from the seeds of Silybum marianum) has been used to date mostly as a hepatoprotectant. However, it also has other interesting activities, e.g., anticancer and hypocholesterolemic effects. It is also known that silybin can inhibit the activities of the cytochrome P450 (P450) enzymes. In this study, a weak interaction of silybin with human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC(50) > or = 250 microM) was found; a moderate inhibition was observed for CYP1A2 and 2C8. The most prominent inhibition effect was found with CYP3A4 and CYP2C9 (IC(50) < or = 50 microM). Using mass spectometry detection, production of O-demethylated (the main metabolite) as well as hydroxylated derivatives of silybin formed by P450 enzymes was detected. The effect of different P450 inhibitors on the formation of O-demethylated product was also studied. In particular, a relatively specific inhibitor of CYP2C8 (quercetin) markedly inhibited the formation of this metabolite. With the help of recombinant enzymes (bactosomes), it was confirmed that the CYP2C8 enzyme is responsible for the reaction leading to O-demethylated silybin.
- 650 _2
- $a antioxidancia $x farmakologie $x metabolismus $7 D000975
- 650 _2
- $a aromatické hydroxylasy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D001189
- 650 _2
- $a oxid uhelnatý $x farmakologie $7 D002248
- 650 _2
- $a katalýza $x účinky léků $7 D002384
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a cytochrom P-450 CYP1A2 $x genetika $x metabolismus $7 D019388
- 650 _2
- $a cytochrom P-450 CYP3A $7 D051544
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x genetika $x metabolismus $7 D003577
- 650 _2
- $a inhibitory enzymů $x farmakologie $x metabolismus $7 D004791
- 650 _2
- $a Escherichia coli $x genetika $x metabolismus $7 D004926
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jaterní mikrozomy $x enzymologie $x metabolismus $x účinky léků $7 D008862
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a quercetin $x farmakologie $7 D011794
- 650 _2
- $a rekombinantní proteiny $x metabolismus $7 D011994
- 650 _2
- $a silymarin $x farmakologie $x chemie $x metabolismus $7 D012838
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a inhibitory cytochromu P450 CYP1A2 $7 D065609
- 650 _2
- $a inhibitory cytochromu P450 $7 D065607
- 700 1_
- $a Anzenbacherová, Eva, $d 1959- $7 stk2008428613
- 700 1_
- $a Papoušková, Barbora $7 xx0137487
- 700 1_
- $a Lemr, Karel, $d 1963- $7 ola2002157903
- 700 1_
- $a Lužná, Pavla, $d 1983- $7 xx0165786
- 700 1_
- $a Veinlichová, A. $7 _AN051220
- 700 1_
- $a Anzenbacher, Pavel, $d 1947- $7 xx0034447
- 700 1_
- $a Šimánek, Vilím, $d 1942- $7 ola200208149
- 773 0_
- $w MED00001446 $t Drug metabolism and disposition $g Roč. 35, č. 11 (2007), s. 2035-2039 $x 0090-9556
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20101103092445 $b ABA008
- 991 __
- $a 20101103134245 $b ABA008
- 999 __
- $a ok $b bmc $g 801912 $s 666672
- BAS __
- $a 3
- BMC __
- $a 2007 $b 35 $c 11 $d 2035-2039 $i 0090-9556 $m Drug metabolism and disposition $n Drug Metab Dispos $x MED00001446
- LZP __
- $a 2010-B3/vtme